PTF1A and respiratory failure: Three (6%) patients experienced treatment-related AEs (TRAEs; not considered DLTs) that led to study discontinuation, including increases in ALT, aspartate aminotransferase (AST), and/or bilirubin, and respiratory failure in one patient with PaCA receiving 7.5 mg/kg.